Biotest AG: Successful Start into 2009
Biotest AG / Quarter Results
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Successful Start into 2009
· Sales and EBIT significantly increased compared to the first quarter in
the previous year
· Operating basis broadened by expansion of capacity and additional
approvals
Dreieich, 15 May 2009. Financial year 2009 started well for Biotest Group.
In the first quarter, the company, which specialises in pharmaceuticals,
biotherapeutics and diagnostics, recorded sales totalling EUR 119.4
million. That represents an increase of 13.2 % compared with the first
three months in 2008 (EUR 105.5 million).
Earnings before interest and taxes (EBIT) were up to EUR 14.4 million which
is an increase by 8.3 % compared to the first quarter in 2008 (EUR 13.3
million).
Biotest has broadened its operating basis by expanding immunglobuline
capacity and obtaining approval for further products in additional markets.
More details on sales and earnings of the four segments as well as on the
progress of the implementation of strategically important projects are
given in Biotest's Quarterly Report as of 31 March 2009. The Quarterly
Report can be seen and downloaded on Biotest's website (www.biotest.com).
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a company that researches and manufactures pharmaceutical,
biotherapeutic and diagnostic products and has specialised in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. The products of the Microbiological Monitoring segment are primarily
used in hygiene monitoring, while those of Medical Diagnostics are used,
for example, in blood transfusions and transplants. Biotest has around
2,000 employees worldwide. The shares of Biotest AG are listed in the SDAX
on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
15.05.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
